iMedicor Signs Agreement with Large Midwest Dental Group

WINDERMERE, Fla., Aug. 26, 2014--iMedicor (OTC: VMCI) announced today that it has signed an agreement with a large dental group, headquartered in the Midwest.  The dental group provides quality, affordable and accessible family dental care with over 100 locations throughout eleven states. Robert McDermott, President and CEO of iMedicor stated, "We are very excited about this agreement as it diversifies and strengthens our customer base nationally. More importantly it demonstrates our ability to add value to our clients by bringing them federally-available funding to convert records from paper to digital format and by making available cutting-edge practice management and communications software required under the Federal Meaningful Use Incentive Program."  

iMedicor works with qualified medical and dental practices throughout the United States to guide healthcare providers through the Federal EHR attestation process for Meaningful Use (MU) incentive funds. The incentive funds can total up to $63,750 per provider beginning with an initial payment of $21,250 in year one and five subsequent payments of $8,500 each of the next five years if the practice continues to meet MU qualifications. iMedicor also provides Electronic Health Records software that can be customized to a practice's specialty. Coupled with the iCore Exchange, providers are now able to easily and securely collaborate, make patient referrals, transmit patient records, order laboratory tests from hundreds of labs around the country and transmit x-ray's or other patient-centric media in a secure HIPAA compliant manner, both inside and outside of their respective network.

ABOUT IMEDICOR

iMedicor is a national provider of secure, HIPAA-compliant software and consulting communication solutions for the healthcare community. iMedicor offers physicians, patients and other healthcare providers the use of a secure, HIPAA-compliant communications network that addresses current federal standards for security and interoperability as defined by Meaningful Use regulations. iMedicor also serves as a leading national Meaningful Use consultancy that assists doctors and dentists to convert from paper to electronic health records (EHRs) while qualifying under Meaningful Use Federal Incentive Funding guidelines.

Forward Looking Statements

In this press release, the use of the words "believe," "could," "expect," "may," "positioned," "project," "projected," "should," "will," "would" or similar expressions is intended to identify forward-looking statements that represent the Company's current judgment about possible future events. The Company believes these judgments are reasonable, but these statements are not guarantees of any events or financial results, and actual results may differ materially due to a variety of important factors.

SOURCE iMedicor

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.